Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Neuromodulation of freezing in Parkinson’s disease

Alfonso Fasano, MD, PhD, University of Toronto, Toronto, Canada, delves into the profound impact of freezing of gait on Parkinson’s disease patients, emphasizing its role in reduced mobility and increased morbidity and mortality. Dr Fasano explores the current challenges and advancements in treating freezing of gait, highlighting the sometimes-limited efficacy of levodopa and the promising avenue of neuromodulation. Specific focus is given to the potential of neuromodulation techniques, from established targets like the subthalamus and globus pallidus to innovative approaches like adaptive deep brain stimulation and spinal cord stimulation. Newer stimulation targets, such as the cerebellum, thalamus, and medial lemniscus, and non-invasive neuromodulation techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) and vagal nerve stimulation are also discussed. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Fasano reports the following disclosures:
Receipt of grants/research support: Boston Scientific, MJ Fox Foundation, Medtronic, University of Toronto, McLaughlin Centre
Receipt of honoraria or consultation fees: Abbott, Abbvie, American Academy of Neurology, Brainlab, Boston Scientific, Ceregate, Chiesi Farmaceutici, Inbrain, International Parkinson and Movement Disorder Society, Ipsen, Medtronic, Novartis, TEVA Canada, UCB pharma, Sunovion
Participation in a company sponsored advisory board: Abbott, Abbvie, Boston Scientific, Ipsen, Medtronic, Sunovion